The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease
Open accessAbstract
A number of distinct β-amyloid (Aβ) variants or multimers have been implicated in Alzheimer's disease (AD), and antibodies recognizing such peptides are in clinical trials. Humans have natural Aβ-specific antibodies, but their diversity, abundance, and function in the general population remain largely unknown. Here, we demonstrate with peptide microarrays the presence of natural antibodies against known toxic Aβ and amyloidogenic non-Aβ species in plasma samples and cerebrospinal fluid of AD patients and healthy controls aged 21–89 years. Antibody reactivity was most prominent against oligomeric assemblies of Aβ and pyroglutamate or oxidized residues, and IgGs specific for oligomeric preparations of Aβ1-42 in particular declined with age and advancing AD. Most individuals showed unexpected antibody reactivities against peptides unique to autosomal dominant forms of dementia (mutant Aβ, ABri, ADan) and IgGs isolated from plasma of AD patients or healthy controls protected primary neurons from Aβ toxicity. Aged vervets showed similar patterns of plasma IgG antibodies against amyloid peptides, and after immunization with Aβ the monkeys developed high titers not only against Aβ peptides but also against ABri and ADan peptides. Our findings support the concept of conformation-specific, cross-reactive antibodies that may protect against amyloidogenic toxic peptides. If a therapeutic benefit of Aβ antibodies can be confirmed in AD patients, stimulating the production of such neuroprotective antibodies or passively administering them to the elderly population may provide a preventive measure toward AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their level inversely correlate with the number of amyloid plaques [97,98].”
From Is there a role for B cells in Alzheimer's disease? (2026) · cites this paper as [97]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These antibodies to toxic forms of A β are present in the plasma and CSF of patients and healthy controls”
From Is there a role for B cells in Alzheimer's disease? (2026) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedRegularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F. Z., Miled, S. B., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,785
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Java Treeview—extensible visualization of microarray data
Saldanha, A. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth349 · Cited by 2,991
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Cited by
Sorted by citations
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Immune activation in brain aging and neurodegeneration: too much or too little?
Lucin, K. M., & Wyss-Coray, T. (2009) · Neuron · doi:10.1016/j.neuron.2009.08.039 · Cited by 679
Self-citationBohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
Lemere, C. A., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.219 · Cited by 351
Self-citationTruncated and modified amyloid-beta species
Kummer, M. P., & Heneka, M. T. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt258 · Cited by 351
Amyloid-β Receptors: The Good, the Bad, and the Prion Protein
Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., & Hooper, N. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.702704 · Cited by 256
Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease
Jawhar, S., Wirths, O., & Bayer, T. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r111.288308 · Cited by 220
Peripheral immune system in aging and Alzheimer’s disease
Cao, W., & Zheng, H. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0284-2 · Cited by 214
Therapeutic B-cell depletion reverses progression of Alzheimer’s disease
Kim, K., Wang, X., Ragonnaud, E., Bodogai, M., Illouz, T., DeLuca, M., McDevitt, R. A., Gusev, F., Okun, E., Rogaev, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22479-4 · Cited by 206
Mouse Models of Alzheimer’s Disease
Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.912995 · Cited by 213
Human B‐1 cells take the stage
Rothstein, T. L., Griffin, D. O., Holodick, N. E., Quách, T. D., & Kaku, H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12137 · Cited by 183
Bayer, T. A., & Wirths, O. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1287-x · Cited by 170
Reiman, E. M., Langbaum, J. B. S., & Tariot, P. N. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.91 · Cited by 160
Immunosenescence: signaling pathways, diseases and therapeutic targets
Fu, Y., Wang, B., Alu, A., Hong, W., Hong, L., He, X., Shi, H., Cheng, P., & Yang, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02371-z · Cited by 168
Natural antibodies – facts known and unknown
Palma, J., Tokarz–Deptuła, B., Deptuła, J., & Deptuła, W. (2018) · Central European Journal of Immunology · doi:10.5114/ceji.2018.81354 · Cited by 136
Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies
Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 130
Dodel, R. C., Balakrishnan, K., Keyvani, K., Deuster, O., Neff, F., Andrei‐Selmer, L., Röskam, S., Stüer, C., Al‐Abed, Y., Noelker, C., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4401-10.2011 · Cited by 129
Reyneveld, G. I., Savelkoul, H. F. J., & Parmentier, H. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02139 · Cited by 118
Price, J. V., Tangsombatvisit, S., Xu, G., Yu, J., Levy, D., Baechler, E. C., Gozani, O., Varma, M., Utz, P. J., & Liu, C. L. (2012) · Nature Medicine · doi:10.1038/nm.2913 · Cited by 102
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
Moreth, J., Mavoungou, C., & Schindowski, K. (2013) · Immunity & Ageing · doi:10.1186/1742-4933-10-18 · Cited by 103
Magga, J. M., Puli, L., Pihlaja, R., Kanninen, K. M., Neulamaa, S., Malm, T., Härtig, W., Grosche, J., Goldsteins, G., Tanila, H., et al. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-90 · Cited by 100
Amyloid-β Immunotherapy for Alzheimers Disease
Fu, H., Liu, B., Frost, J. L., & Lemere, C. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012017 · Cited by 92
Self-citationSolanezumab for the treatment of mild-to-moderate Alzheimer’s disease
Imbimbo, B. P., Ottonello, S., Frisardi, V., Solfrizzi, V., Greco, A., Seripa, D., Pilotto, A., & Panza, F. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.93 · Cited by 93
Jianming, W., & Ling, L. (2016) · The Journal of Biomedical Research · doi:10.7555/jbr.30.20150131 · Cited by 87
Späni, C., Suter, T., Derungs, R., Ferretti, M. T., Welt, T., Wirth, F., Gericke, C., Nitsch, R. M., & Kulic, L. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0251-x · Cited by 88
Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease
Lobello, K., Ryan, J. M., Liu, E., Rippon, G. A., & Black, R. S. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/628070 · Cited by 93
Loeffler, D. A. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230025 · Cited by 90
B in TB: B Cells as Mediators of Clinically Relevant Immune Responses in Tuberculosis
Rao, M., Valentini, D., Poiret, T., Dodoo, E., Parida, S. K., Zumla, A. I., Brighenti, S., & Maeurer, M. J. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ614 · Cited by 81
Autoantibody Profiling in Multiple Sclerosis Using Arrays of Human Protein Fragments
Ayoglu, B., Månberg, A., Khademi, M., Olsson, T. P., Uhlén, M., Schwenk, J. M., & Nilsson, P. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.026757 · Cited by 80
High-throughput identification of autoantibodies that target the human exoproteome
Wang, E. Y., Dai, Y., Rosen, C. E., Schmitt, M. M., Dong, M. X., Ferré, E. M. N., Liu, F., Yang, Y., González-Hernández, J. A., Meffre, E., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100172 · Cited by 76
Blood-Borne Amyloid-β Dimer Correlates with Clinical Markers of Alzheimer's Disease
Villemagne, V. L., Perez, K. A., Pike, K. E., Kok, W. M., Rowe, C. C., White, A. R., Bourgeat, P., Salvado, O., Bedő, J., Hutton, C. A., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.5180-09.2010 · Cited by 72
Non human primate models for Alzheimer’s disease-related research and drug discovery
Dam, D. V., & Deyn, P. P. D. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1271320 · Cited by 73
How the immune system shapes neurodegenerative diseases
Mason, H. D., & McGavern, D. B. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.08.001 · Cited by 67
Antibody-based therapy in Alzheimer's disease
Pul, R., Dodel, R. C., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 59
Srivastava, A., Das, B., Yao, A. Y., & Yan, R. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201146 · Cited by 58
Beta-amyloid auto-antibodies are reduced in Alzheimer's disease
Qu, B.-X., Gong, Y., Moore, C., Fu, M., German, D. C., Chang, L.-Y., Rosenberg, R., & Diaz-Arrastia, R. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.06.017 · Cited by 47
Claes, C., England, W. E., Danhash, E. P., Kiani Shabestari, S., Jairaman, A., Chadarevian, J. P., Hasselmann, J., Tsai, A. P., Coburn, M. A., Sanchez, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12577 · Cited by 52
Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged
Rothstein, T. L. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00127 · Cited by 50
Nimmo, J., Verma, A. K., Dodart, J., Wang, C. Y., Savistchenko, J., Melki, R., Carare, R. O., & Nicoll, J. A. R. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00727-x · Cited by 48
Measurement of anti-beta amyloid antibodies in human blood
Szabo, P., Mujalli, D. M., Rotondi, M. L., Sharma, R., Weber, A., Schwarz, H., Weksler, M. E., & Relkin, N. R. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.06.010 · Cited by 49
Marciani, D. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13608 · Cited by 48
Antigen Arrays for Profiling Autoantibody Repertoires
Ayoglu, B., Schwenk, J. M., & Nilsson, P. (2016) · Bioanalysis · doi:10.4155/bio.16.31 · Cited by 49
Pathogenic and physiological autoantibodies in the central nervous system
Gold, M., Pul, R., Bach, J., Stangel, M., & Dodel, R. C. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01128.x · Cited by 47
Alzheimer's disease vaccine development: A new strategy focusing on immune modulation
Marciani, D. J. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.08.008 · Cited by 45
Maetzler, W., Apel, A., Langkamp, M., Deuschle, C., Dilger, S. S., Stirnkorb, J. G., Schulte, C., Schleicher, E. D., Gasser, T., & Berg, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088604 · Cited by 46
Liu, Y., Wang, J., Li, Q., Fowler, C. J., Zeng, F., Deng, J., Xu, Z., Zhou, H., Doecke, J. D., Villemagne, V. L., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb0457 · Cited by 47
Davtyan, H., Mkrtichyan, M., Movsesyan, N., Petrushina, I., Mamikonyan, G., Cribbs, D. H., Agadjanyan, M. G., & Ghochikyan, A. (2009) · Gene Therapy · doi:10.1038/gt.2009.140 · Cited by 43
Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease
Wirths, O., & Zampar, S. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1702972 · Cited by 44
Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications
Chantran, Y., Capron, J., Alamowitch, S., & Aucouturier, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01534 · Cited by 42
Sagare, A. P., Bell, R. D., Srivastava, A., Sengillo, J. D., Singh, I., Nishida, Y., Chow, N., & Zloković, B. V. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.439570 · Cited by 42
Differential recognition of vascular and parenchymal beta amyloid deposition
Rutgers, K. S., van Remoortere, A., van Buchem, M. A., Verrips, C. T., Greenberg, S. M., Bacskai, B. J., Frosch, M. P., van Duinen, S. G., Maat–Schieman, M. L. C., & van der Maarel, S. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.012 · Cited by 40
Rasool, S., Albay, R., Martínez‐Coria, H., Breydo, L., Wu, J., Milton, S. C. F., Misra, S., Tran, A. T., Pensalfini, A., LaFerla, F. M., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-37 · Cited by 38
Ordóñez‐Gutiérrez, L., Posado-Fernández, A., Ahmadvand, D., Lettiero, B., Wu, L., Antón, M., Flores, O., Moghimi, S. M., & Wandosell, F. G. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.027 · Cited by 40
Protein Clearance Mechanisms of Alpha-Synuclein and Amyloid-Beta in Lewy Body Disorders
Deleidi, M., & Maetzler, W. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/391438 · Cited by 40
Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D., Solfrizzi, V., & Pilotto, A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.579099 · Cited by 38
Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections
Ferrara, G., Zumla, A. I., & Maeurer, M. J. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.01.023 · Cited by 38
The immunology of B-1 cells: from development to aging
Mattos, M. S., Vandendriessche, S., Waisman, A., & Marques, P. E. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00455-y · Cited by 39
Can peripheral leukocytes be used as Alzheimer’s disease biomarkers?
Rezai-Zadeh, K. P., Gate, D., Szekely, C. A., & Town, T. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.118 · Cited by 36
Marciniuk, K., Taschuk, R., & Napper, S. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/473706 · Cited by 39
Decoding the autoantibody reactome
Jaycox, J. R., Dai, Y., & Ring, A. M. (2024) · Science · doi:10.1126/science.abn1034 · Cited by 37
Immunosenescence as a convergence pathway in neurodegeneration
Mohapatra, L., Mishra, D. K., Tripathi, A. S., & Parida, S. K. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110521 · Cited by 38
Systemic and Central Immunity in Alzheimer's Disease: Therapeutic Implications
Butchart, J., & Holmes, C. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00245.x · Cited by 36
Alzheimer Disease Pathogenesis: The Role of Autoimmunity
Lim, B., Prassas, I., & Diamandis, E. P. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa171 · Cited by 36
New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies
Marciani, D. J. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.02.015 · Cited by 34
Mengel, D., Röskam, S., Neff, F., Balakrishnan, K., Deuster, O., Gold, M., Oertel, W. H., Bacher, M., Bach, J.-P., & Dodel, R. C. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.151 · Cited by 34
The Appendix in Parkinson’s Disease: From Vestigial Remnant to Vital Organ?
Killinger, B. A., & Labrie, V. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191703 · Cited by 36
Severini, C., Barbato, C., Certo, M. G. D., Gabanella, F., Petrella, C., Stadio, A. D., VINCENTIIS, M. D., Polimeni, A., Ralli, M., & Greco, A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200621204546 · Cited by 34
Specificity of Adaptive Immune Responses in Central Nervous System Health, Aging and Diseases
Rickenbach, C., & Gericke, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.806260 · Cited by 33
Marciani, D. J. (2019) · Research · doi:10.34133/2019/5341375 · Cited by 33
Characterization of AβpN3 deposition in the brains of dogs of various ages and other animal species
CHAMBERS, J. K., Mutsuga, M., Uchida, K., & Nakayama, H. (2011) · Amyloid · doi:10.3109/13506129.2011.570385 · Cited by 31
Citrullination of Amyloid-β Peptides in Alzheimer’s Disease
Mukherjee, S., Perez, K. A., Dubois, C., Nisbet, R. M., Li, Q., Varghese, S., Jin, L., Birchall, I. E., Streltsov, V. A., Vella, L. J., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00474 · Cited by 30
Are fibrinaloid microclots a cause of autoimmunity in Long Covid and other post-infection diseases?
Kell, D. B., & Pretorius, E. (2023) · Biochemical Journal · doi:10.1042/bcj20230241 · Cited by 34
Schmelter, C., Perumal, N., Funke, S., Bell, K. C., Pfeiffer, N., & Grus, F. H. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx332 · Cited by 29
Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases
Kocurova, G., Říčný, J., & Ovsepian, S. V. (2022) · Theranostics · doi:10.7150/thno.72126 · Cited by 29
Morrone, C. D., Liu, M., Black, S. E., & McLaurin, J. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00064 · Cited by 26
Marcello, A., Wirths, O., Schneider-Axmann, T., Degerman-Gunnarsson, M., Lannfelt, L., & Bayer, T. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.011 · Cited by 29
Humoral determinants of checkpoint immunotherapy
Dai, Y., Aizenbud, L., Qin, K., Austin, M. R., Jaycox, J. R., Cunningham, J., Wang, E. Y., Zhang, L., Fischer, S., Carroll, S. M., et al. (2025) · Nature · doi:10.1038/s41586-025-09188-4 · Cited by 29
Zhao, M., Wang, S., Wang, Y., Zhang, R., Li, Y., Su, Y.-J., Zhou, W.-W., Yu, X., & Liu, R. (2014) · Current Alzheimer Research · doi:10.2174/15672050113106660176 · Cited by 28
Dhanwani, R., Pham, J. W., Premlal, A. L. R., Frazier, A., Kumar, A., Pero, M. E., Bartolini, F., Dutra, J. R., Marder, K. S., Peters, B., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00874 · Cited by 29
Muir, R. T., Ismail, Z., Black, S. E., & Smith, E. E. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13510 · Cited by 27
Comparison of Intravenous Immunoglobulins for Naturally Occurring Autoantibodies against Amyloid-β
Balakrishnan, K., Andrei‐Selmer, L., Selmer, T., Bacher, M., & Dodel, R. C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1353 · Cited by 28
Bell, K. C., Wilding, C., Funke, S., Pfeiffer, N., & Grus, F. H. (2015) · BMC Ophthalmology · doi:10.1186/s12886-015-0044-9 · Cited by 28
Autoreactive‐Aβ antibodies promote APP β‐secretase processing
Deng, J., Hou, H., Giunta, B. N., Mori, T., Wang, Y., Fernandez, F., Weggen, S., Araki, W., Obregon, D. F., & Tan, J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07629.x · Cited by 28
Klaver, A. C., Coffey, M. P., Smith, L. M., Bennett, D. A., Finke, J. M., Dang, L., & Loeffler, D. A. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-93 · Cited by 28
Tolédano, A., Álvarez, M. I., López-Rodríguez, A. B., Toledano‐Díaz, A., & Fernández, C. I. (2012) · Neurología (English Edition) · doi:10.1016/j.nrleng.2012.07.002 · Cited by 29
Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia
Kronimus, Y., Albus, A., Balzer‐Geldsetzer, M., Straub, S., Semler, E., Otto, M., Klotsche, J., Dodel, R. C., & Mengel, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164953 · Cited by 26
The role of autoantibodies in bridging obesity, aging, and immunosenescence
Valentino, T. R., Chen, N., Makhijani, P., Khan, S. M., Winer, S., Revelo, X. S., & Winer, D. A. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00489-2 · Cited by 27
An impedimetric assay of α-synuclein autoantibodies in early stage Parkinson's disease
Xu, Q., Evetts, S. G., Hu, M., Talbot, K., Wade‐Martins, R., & Davis, J. J. (2014) · RSC Advances · doi:10.1039/c4ra10100f · Cited by 25
Distinct Patterns of Antiamyloid-β Antibodies in Typical and Atypical Alzheimer Disease
Dorothée, G., Bottlaender, M., Moukari, E., de Souza, L. C., Maroy, R., Corlier, F. W., Colliot, O., Marie Chupin, A., Lamari, F., Lehéricy, S., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.604 · Cited by 25
Peripheral Routes to Neurodegeneration: Passing Through the Blood–Brain Barrier
Giannoni, P., Claeysen, S., Noè, F. M., & Marchi, N. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00003 · Cited by 25
The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease
Sim, K.-Y., Im, K. C., & Park, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155295 · Cited by 24
A Perspective on Roles Played by Immunosenescence in the Pathobiology of Alzheimer's Disease
Zhao, Y. G., Zhan, J., & Liu, Y. (2020) · Aging and Disease · doi:10.14336/ad.2020.0205 · Cited by 23
Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer’s disease
Zhang, L., Liang, X., Zhang, Z., & Luo, H. (2021) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545822300014 · Cited by 24
Autoantibodies to Interferons in Infectious Diseases
Quirós-Roldán, E., Sottini, A., Signorini, S. G., Serana, F., Tiecco, G., & Imberti, L. (2023) · Viruses · doi:10.3390/v15051215 · Cited by 24
Valentini, D., Rao, M., Rane, L., Rahman, S., Axelsson‐Robertson, R., Heuchel, R. L., Löhr, M. J., Hoft, D. F., Brighenti, S., Zumla, A. I., et al. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.01.027 · Cited by 23
Alzheimer's disease and Down's syndrome: Treating two paths to dementia
Weksler, M. E., Szabo, P., Relkin, N. R., Reidenberg, M. M., Weksler, B. B., & Coppus, A. M. W. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.10.013 · Cited by 22
Kou, J., Yang, J., Lim, J.-E., Pattanayak, A., Song, M., Planque, S. A., Paul, S., & Fukuchi, K.-I. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8691-z · Cited by 22
Conti, E., Galimberti, G., Tremolizzo, L., Masetto, A., Cereda, D., Zanchi, C., Piazza, F., Casati, M., Isella, V., Appollonio, I. M., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.09.050 · Cited by 20
Levites, Y., O’Nuallain, B., Puligedda, R. D., Ondrejčák, T., Adekar, S. P., Chen, C. S., Cruz, P. E., Rosario, A. M., Macy, S. D., Mably, A. J., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.5109-14.2015 · Cited by 21
Innate and adaptive immunity in neurodegenerative disease
Huang, Y., Zhang, G., Li, S., Feng, J., & Zhang, Z. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05533-4 · Cited by 22
Metadata
- Authors
- Britschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., Clark, C. M., Fagan, A. M., Galasko, D. R., Holtzman, D. M., Jutel, M., Kaye, J. A., Lemere, C. A., Leszek, J., Li, G., Peskind, E. R., Quinn, J. F., Yesavage, J. A., Ghiso, J. A., & Wyss-Coray, T.
- Affiliations
- Stanford Medicine (US)
- Stanford University (US)
- Departments of aNeurology and Neurological Sciences and
- University of Zurich (CH)
- VA Palo Alto Health Care System (US)
- University of Pennsylvania (US)
- Washington University in St. Louis (US)
- University of California San Diego (US)
- Wroclaw Medical University (PL)
- Oregon Health & Science University (US)
- Brigham and Women's Hospital (US)
- University of Washington (US)
- NYU Langone Health (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-07-21
- Volume
- 106
- Issue
- 29
- Pages
- 12145-12150
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2715538
- OpenAlex
- W2132576841
- Cited by
- 201
- References
- 65
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 8 · 2023: 11 · 2022: 16 · 2021: 9 · 2020: 15 · 2019: 7 · 2018: 5 · 2017: 4 · 2016: 16 · 2015: 12 · 2014: 10 · 2013: 12 · 2012: 20
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institute on Aging (P01AG010491, AG10491, AG 08017, AG20603, R01AG020603, P30AG008017, R01AG030539, AG030539, P50AG005136)
- National Institute of Neurological Disorders and Stroke (R01NS136122)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, natural antibodies, amyloid-beta, amyloid oligomers, neuroprotection, aging, cerebrospinal fluid, plasma IgG, pyroglutamic acid, ABRI, Adán, conformation-specific antibodies, vervet monkey, immunization, passive immunotherapy, peptide microarrays
- MeSH terms
- Aging, Alzheimer Disease, Animals, Antibodies, Dementia, Genes, Dominant, Immunoglobulin G, Immunization, Molecular Weight, Neurons, Peptides, Primates, Protein Processing, Post-Translational, Amyloid beta-Peptides, Disease Progression, Neuroprotective Agents, Cytoprotection, Protein Structure, Quaternary, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
